Refractory Mantle Cell Lymphoma

Refractory Mantle Cell Lymphoma is the indication for 6 drugs in DrugBank. It is covered by 7 curated, structured indications.

Also known as: Mantle Cell Lymphoma Refractory · Refractory Mantle Cell Lymphoma (MCL)
Classified under: Hematologic Neoplasms
Indicated drugs: Bendamustine
Brexucabtagene autoleucel
Ibrutinib
Lisocabtagene maraleucel
Pirtobrutinib
Sonrotoclax

Resolves to

Vocabularies

MedDRA10026801UMLSC0855138

What you can answer from here — as of November 13, 2026

6Indicated drugsWith each drug's targets and mechanism

Listed above

7Structured indicationsPopulation, line of therapy, route and combination as fields, not prose

68Clinical trialsPhase, status and sponsor resolved per trial

1Drug reporting it as an adverse effectWith incidence where the label states it

Which approved drugs for Refractory Mantle Cell Lymphoma share a target, and which companies have late-stage candidates against it?

Create a free account or log in to explore the full data card.